IQVIA Holdings Inc. (NYSE:IQV) Stake Raised by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 454,984 shares of the medical research company’s stock after acquiring an additional 4,240 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.25% of IQVIA worth $107,818,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Canada Pension Plan Investment Board raised its position in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after acquiring an additional 211,653 shares in the last quarter. Farallon Capital Management LLC raised its holdings in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after buying an additional 86,870 shares during the period. Impax Asset Management Group plc raised its holdings in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares during the period. Legal & General Group Plc raised its holdings in IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after buying an additional 11,715 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in IQVIA by 5.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock worth $253,125,000 after buying an additional 60,827 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 1.4 %

Shares of NYSE IQV opened at $201.24 on Wednesday. The business has a 50 day simple moving average of $221.18 and a 200 day simple moving average of $226.75. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $36.53 billion, a price-to-earnings ratio of 26.41, a PEG ratio of 2.10 and a beta of 1.51.

Analyst Ratings Changes

Several research firms have issued reports on IQV. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Morgan Stanley cut their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Truist Financial lowered their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.